Clinical Outcomes and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A Real-World Data Analysis

TL;DR

This study examines clinical outcomes and treatment patterns in metastatic triple-negative breast cancer patients using real-world data from Japan.

Contribution

The study identifies prognostic factors and treatment feasibility in metastatic triple-negative breast cancer using real-world data.

Findings

31% of patients could not receive systemic treatment due to poor condition.

Median overall survival was 14 months among treated patients with an average of 2.2 treatment lines.

Number of metastatic organs and treatment with paclitaxel plus bevacizumab were associated with overall survival.

Abstract

Metastatic triple-negative breast cancer (mTNBC) is associated with poor outcomes, and therapeutic strategies remain challenging. This study analyzed real-world data to clarify clinical characteristics, treatment patterns, and survival outcomes, focusing on treatment feasibility at metastatic diagnosis.

A retrospective analysis was conducted on 96 Japanese women who developed distant metastasis after curative surgery and met the inclusion criteria for the final analysis. Patients who were unable to receive drug treatment due to poor condition were defined as the non-treated group and compared with the treated group, who received at least 4 weeks of systemic therapy. Overall survival was assessed using the Cox proportional hazard model.

Overall, 31% of patients could not receive systemic treatment due to poor condition. The non-treated group was more frequently diagnosed after presenting with symptoms and had a higher prevalence of poor performance status and brain metastasis (P < 0.001). Among the 66 treated patients, the median overall survival was 14 months with an average of 2.2 treatment lines. In exploratory Cox analyses, the number of metastatic organs and treatment with paclitaxel plus bevacizumab were associated with overall survival. Several patients experienced prolonged treatment with oral 5-fluorouracil.

A significant proportion of patients were diagnosed with mTNBC after symptom onset, limiting therapeutic intervention. Diagnosing mTNBC before symptomatic deterioration may expand treatment opportunities. Prospective evaluation of follow-up strategies and biomarkers is required, and further research should clarify treatment positioning, including paclitaxel plus bevacizumab and maintenance therapy with oral agents for biologically low-grade cases.

Figures